Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile...

MHRA issued device safety information for healthcare professionals managing patients receiving continuous renal replacement therapy. The agency says caspofungin can bind to polyacrylonitrile filter membranes and reduce antifungal effectiveness, with the greatest potential risk when a new membrane or circuit starts.

Why it matters: MHRA identifies filter changes and drug administration timing as factors in potential loss of antifungal effectiveness during concurrent treatment.